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Background: This study investigates the efficacy of a complex multifaceted intervention aiming at increasing the
quality of care of GPs for patients with multimorbidity. In its core, the intervention aims at enhancing the
doctor-patient-dialogue and identifying the patient’s agenda and needs. Also, a medication check is embedded.
Our primary hypothesis is that a more patient-centred communication will reduce the number of active
pharmaceuticals taken without impairing the patients’ quality of life. Secondary hypotheses include a better
knowledge of GPs about their patients’ medication, a higher patient satisfaction and a more effective and/or
efficient health care utilization.
Methods/design: Multi-center, parallel group, cluster randomized controlled clinical trial in GP surgeries. Inclusion
criteria: Patients aged 65–84 years with at least 3 chronic conditions. Intervention: GPs allocated to this group will
receive a multifaceted educational intervention on performing a narrative doctor-patient dialogue reflecting treatment
targets and priorities of the patient and on performing a narrative patient-centred medication review. During the one
year intervention GPs will have a total of three conversations à 30 minutes with the enrolled patients. Control: Care as
usual. Follow-up per patient: 14 months after baseline interview. Primary efficacy endpoints: Differences in medication
intake and health related quality of life between baseline and follow-up in the intervention compared to the control
group. Randomization: Computer-generated by an independent institute. It will be performed successively when
patient recruitment in the respective surgery is finished. Blinding: Participants (GPs and patients) will not be blinded to
their assignment but will be unaware of the study hypotheses or outcome measures.
Discussion: There is growing evidence that the phenomenon of polypharmacy and low quality of drug use is
substantially due to mis-communication (or non-communication) in the doctor patient interaction. We assume that the
number of pharmaceutical agents taken can be reduced by a communicational intervention and that this will not
impair the patients’ health-related quality of life. Improving communication is a core issue of future interventions,
especially for patients with multimorbidity.
Trial registration: Current Controlled Trials ISRCTN46272088.
Keywords: Multimorbidity, Primary care, Randomised controlled trial, Polypharmacy, Narrative based medicine* Correspondence: in.schaefer@uke.de
2Department of Primary Medical Care, University Medical Center
Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
Full list of author information is available at the end of the article
© 2012 Altiner et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Altiner et al. BMC Family Practice 2012, 13:118 Page 2 of 8
http://www.biomedcentral.com/1471-2296/13/118Background
Multimorbidity can be defined as the coexistence of at least
2 chronic diseases [1]. Care for patients with multimorbidity
is a complex task for the GP because of several reasons:
Multimorbidity reduces adherence, produces conflicts in
treatment decisions due to contra-indications for other dis-
eases, causes polypharmacy and is not supported by clinical
guidelines [2]. In caring for patients with multimorbidity a
special focus is on coordinating care and integrating differ-
ent needs of the patient and the medical treatment. A model
for optimal care for patients with multimorbidity does not
exist. However, the chronic care model [3] opens up a per-
spective as it highlights elements that are necessary for opti-
mal chronic illness care on the level of the single patient.
These elements relate to [4]:
 the joint definition of problems by patient and
physician,
 targeting, goal setting and planning,
 a continuum of self-management training and
support services, and
 active and sustained follow-up by the professional.Up to date it is not known how these elements can be
realized in practice. The few intervention studies carried
out for improving outcomes in patients with multimor-
bidity in primary care and community settings involved
complex interventions with multiple elements including
also changes to the organisation of care delivery. The
results suggest that interventions to date have had mixed
effects but have shown a tendency to improve prescrib-
ing and medication adherence [5]. Other studies focused
on interventions to improve appropriate polypharmacy.
In a systematic review Patterson et al. concluded that it
is unclear if the interventions studied resulted in a clin-
ically significant improvement, but they appeared benefi-
cial in terms of reducing inappropriate prescribing and
medication-related problems [6].
It is also not known which specific aspects of care for
patients with multimorbidity by German GPs can and
should be optimized within the available resources and
which of them have a realistic chance to show sustained
effects. What we do know is that German GPs see their
patients very often for a short time at each visit. German
doctors in ambulatory care see 243–309 patients a week,
much more than e.g. UK doctors with 154–205 contacts.
It is understood that this number includes a number of
patients without face to face contact (e.g. repeated drug
prescriptions [7]). This high contact frequency results in
a contact duration of only 7.6-7.8 minutes per patient
[8,9]. These and other research results [10] suggest that
the elements of chronic illness care mentioned above
may insufficiently be put into practice as they afford aconsiderable amount of communication time. Routine
doctor-patient consultation is usually determined by real
and by perceived time-constraints and a by doctor-
centred consultation-style.
The concept of “narrative based medicine” was estab-
lished by Greenhalgh et al. [11] in order to stop this nega-
tive development. The concept assumes that patient
narratives of illness can provide a framework for approach-
ing a patient’s problems holistically and may uncover diag-
nostic and therapeutic options. This concept has not yet
been linked to the Chronic Care Model.
The MultiCare AGENDA study investigates the effi-
cacy of a complex multifaceted intervention aiming at
increasing the quality of care of GPs for patients with
multimorbidity. When treating patients with multimor-
bidity it is crucial to prioritize and set goals. Only if the
patient perspective is known, the main focus of treat-
ment can be defined. Therefore in its core, the interven-
tion aims at enhancing the doctor-patient-dialogue and
identifying the patient’s agenda and needs, including the
need for social support. Also, a medication check is em-
bedded in this intensified dialogue. Our primary hypoth-
esis is that a more patient-centred communication can
disclose the main focus of treatment of the patient
which often will have implications for medication use.
Therefore the primary hypothesis is that the patient-
centered communication in the form of narrative based
medicine leads to a reduction of the number of medica-
tion taken without reducing health related quality of life.
Rationale of the hypothesis
In a pilot study [12] we developed and evaluated an
intervention package that is based on constitutional ele-
ments of the Chronic Care Model and the concept of
narrative based medicine as presented above.
In a first step we conducted qualitative in-depth inter-
views with 10 GPs and two of their multimorbid patients
respectively. We found that GPs and their multimorbid
patients pursued different agendas. Patients focused on
restrictions in their activities of daily living and their fear of
becoming dependent on others. The GPs knew about these
restrictions variably well but focussed rather on medical
diagnoses and risk factors of their patients. Patients and
GPs appreciated very much the opportunity to meet each
other regularly. Narrative interviews were perceived as a
good opportunity to reflect about the treatment experi-
ences and they were experienced by both as a good stimu-
lus to address certain issues at the next meeting.
Surprisingly, in this pilot study polypharmacy was only a
side issue for both patients and GPs although the
phenomenon was apparently existent. We concluded that
there is a need for a regular revision and readjustment of
treatment goals between the GP and his patient. Regular
consultations outside the normal routine, scheduled twice
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tive based approach might be a better way of identifying
problems and the agenda of the patient than e.g. prede-
fined problem check lists etc. Also, it might be important
to draw the attention of the patient and his GP on poly-
pharmacy by means of a comprehensive but still “attract-
ive” narrative medication check.
The concept of an intervention based on these conclu-
sions was positively evaluated within focus group discus-
sions in Hamburg and Dusseldorf. The majority of
participating GPs were quite enthusiastic about the sug-
gested interventional elements. The focus groups showed
the general acceptability of the suggested intervention and
helped to “fine tune” some elements for the final interven-
tion concept.
In a second step we conducted a feasibility study with
16 GPs in Hamburg and Dusseldorf and 135 patients with
multimorbidity. Additional 5 GPs participated in the first
training on narrative-based communication but then, due to
time constraints, did not recruit any patients and were
excluded from the study. The participating GPs were trained
in narrative-based communication and narrative medication
review and performed the scheduled consultations within
the project as planned. We could show the feasibility of the
elaborated concept, both the concept of the intervention it-
self and the study design.
Methods/design
Design
MultiCare AGENDA is designed as a two-armed cluster-
randomized controlled trial in general practice. The
study will evaluate the efficacy of structured, narrative-
based, doctor-patient-dialogues in patients with multimor-
bidity. Given that to date no clinical trial has investigated
the efficacy of this approach the narrative based interven-
tion must be tested against care as usual.
Intervention
GPs allocated to the intervention arm will receive an educa-
tional intervention: (1) on performing a narrative doctor-
patient-dialogue reflecting treatment targets and priorities of
the patient, and (2) on performing a narrative patient-
centred medication review.
During the one year intervention GPs will have a total
of three conversations with the enrolled patients instead
of routine consultations. Each conversation is scheduled
for about 30 minutes. The first conversation will focus
on treatment targets and priorities of the patient, the
second will focus on the medication taken by the patient
and the third will combine the elements of both previ-
ous conversations.
The idea behind the approach of installing a structured
framework of regular consultations is that this will eventu-
ally reduce the high number of (often unscheduled)consultations. The concept of narrative medicine shall fa-
cilitate the development of the patient’s own agenda.
Follow-up per patient: 14 months after the baseline
interview; duration of intervention per patient: 12 months;
all additional treatments are allowed.
GPs of the control group will perform care as usual and at
the end of the intervention they will be offered to participate
in a similar educational intervention as in the intervention
group given. This offer will outweigh the possible lower level
of motivation of these GPs of having been randomised to
the control arm. GPs of the control group will also be finan-
cially recompensated equally to the GPs of the intervention
group.Study population and recruitment
The study will be conducted in three larger German cities, i.
e. Hamburg, Dusseldorf and Rostock. In each study centre
GPs will be randomly selected from the register of the Asso-
ciation of Statutory Health Insurance Physicians and asked
by mail to participate in our study. Additionally, we will re-
cruit GPs using advertisements in internet and print media.
Inclusion criteria for GPs are:
 willingness to participate in the study regardless of
randomisation to the intervention or control arm,
 establishment of an own GP surgery for 2 years at
least, and
 usage of practice software that is able to create a
total list of patients based on age.
Exclusion criteria for GPs are participation in our
feasibility study or the MultiCare Cohort Study [13].
Participating GPs will retrieve a list of all patients aged
between 65 and 84 years who have consulted them
within the last completed quarter (i.e. 3 month period).
From this list 25 patients will be selected randomly
(using random number tables), checked for exclusion
criteria and – if eligible for the study – invited to partici-
pate in the study by a letter from their GP. In case of
interest, the patient will consult the GP and receive writ-
ten and verbal information. The information covers aims
and procedures of the study, selection of participants,
data collection, processing and storage as well as possi-
bilities for cancellation. In case of acceptance, partici-
pants will have to sign an informed consent form to
participate in the study.
Exclusion criteria for patients are:
 Poorly known patients to the GP because of
accidental consultation,
 Patients known by the GP for less than 12 months,
 Insufficient ability to consent (e.g. dementia),
 Insufficient ability to participate in interviews (e.g.
psychic illness),
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according to the GP,
 Residence in a nursing home,
 Deafness,
 Insufficient ability to speak and read German, and
 Participation in other scientific trials.
Inclusion criteria: Only patients with at least 3 chronic
conditions out of a list of 42 diagnosis groups will be
included in the study. This list includes the following
diagnosis groups:
 Severe vision reduction [H17-H18, H25-H28, H31,
H33, H34.1-H34.2, H34.8-H34.9, H35-H36, H40,
H43, H47, H54],
 Joint arthrosis [M15-M19],
 Diabetes mellitus [E10-E14],
 Chronic ischemic heart disease [I20-I21, I25],
 Thyroid dysfunction [E01-E05, E06.1-E06.3, E06.5,
E06.9, E07],
 Cardiac arrhythmias [I44-I45, I46.0, I46.9, I47-I48,
I49.1-I49.9],
 Obesity [E66],
 Purine/pyrimidine metabolism disorders/Gout [E79,
M10],
 Prostatic hyperplasia [N40],
 Lower limb varicosis [I83, I87.2],
 Liver diseases [K70, K71.3-K71.5, K71.7, K72.1,
K72.7, K72.9, K73-K74, K76],
 Depression [F32-F33],
 Asthma/COPD [J40-J45, J47],
 Noninflammatory gynaecological problems [N81,
N84-N90, N93, N95],
 Atherosclerosis/PAOD [I65-I66, I67.2, I70, I73.9],
 Osteoporosis [M80-M82],
 Renal insufficiency [N18-N19],
 Cerebral ischemia/Chronic stroke [G45, I60-I64,
I69],
 Cardiac insufficiency [I50],
 Severe hearing loss [H90, H91.0, H91.1, H91.3,
H91.8, H91.9],
 Chronic cholecystitis/Gallstones [K80, K81.1],
 Somatoform disorders [F45],
 Hemorrhoids [I84],
 Intestinal diverticulosis [K57],
 Rheumatoid arthritis/Chronic polyarthritis
[M05-M06, M79.0],
 Cardiac valve disorders [I34-I37],
 Neuropathies [G50-G64],
 Dizziness [H81-H82, R42],
 Urinary incontinence [N39.3-N39.4, R32],
 Urinary tract calculi [N20],
 Anemias [D50-D53, D55-D58, D59.0-D59.2,
D59.4-D59.9, D60.0, D60.8, D60.9, D61, D63-D64], Anxiety [F40-F41],
 Psoriasis [L40],
 Migraine/chronic headache [G43, G44],
 Parkinson’s disease [G20-G22],
 Cancers [C00-C26, C30-C41, C43-C58, C60-C97,
D00-D09, D37-D48],
 Allergies [H01.1, J30, K52.2, K90.0, L23, L27.2,
L56.4, T78.1, T78.4, T88.7],
 Chronic gastritis/GERD [K21, K25.4-K25.9,
K26.4-K26.9, K27.4-K27.9, K28.4-K28.9,
K29.2-K29.9],
 Sexual dysfunction [F52, N48.4],
 Insomnia [F51, G47],
 Tobacco abuse [F17], and
 Hypotension [I95].
The criterion of at least three chronic diseases or dis-
ease complexes out of a predefined list was chosen in
order to include patients, for whom the diseases repre-
sent a certain burden and who we can expect to use a
considerable amount of medication [14]. Preliminary
data of the baseline assessment in the MultiCare Cohort
Study [9] show that patients included along the above
listed criteria averagely use 7.26 medications (median 7).
Hence there is potential for reduction. The exclusion
criteria shall ensure that patients included into the study
are able to actively participate in the intervention. The
study population will be representative of patients with
multimorbidity in primary care who can communicate
with their GP.Randomization
The randomization will be carried out as a cluster
randomization, in which the GPs will be allocated either to
the intervention or to the control group. Randomization
will be performed successively when patient recruitment in
the respective surgery is finished. It will be performed by an
experienced independent institute (Institute for Biometry,
Hannover Medical School).Primary outcome measures
The first primary outcome measure is the number of
pharmaceutical agents taken by the patients. This meas-
ure will be assessed as a part of the patient interview in
form of a complete medication survey. The interviewer
will collect data on all pharmaceutical products used by
the patient within the last twelve months. The data in-
clude product name, pharmaceutical form, German na-
tional drug code (“Pharmazentralnummer” - PZN -),
periodic or prn (pro re nata) medication, dosage and fre-
quency (for periodic medication). The interviewer will
ask the patient to show the packages of the pharmaceu-
ticals to get the most valid information. If product name
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for the medical indication of the drugs.
The second primary outcome measure is health related
quality of life as measured by the EQ-5D [15]. These data
will also be collected as a part of the patient interview.
Study hypotheses
We assume that the number of pharmaceutical agents
taken by the patient can be reduced in the intervention
group. We will compare the change in medication intake
between baseline and follow-up in the intervention and
control group. We expect that the mean difference be-
tween the changes in both groups will be at least 1.5
drugs less in the intervention group. A minimum differ-
ence of 0.5 drugs between both groups is defined as clin-
ically relevant.
It is assumed that a reduction of medications used will
not impair quality of life. We will compare the change in
health related quality of life between baseline and
follow-up in the intervention and control group. We ex-
pect that the mean change in the intervention group will
not be statistically significantly inferior to the mean
change in the control group.
Secondary outcome measures
We will assess the following secondary outcome measures:
a. GP’s knowledge about the medication taken by the
patient (including GP’s own prescriptions,
prescriptions of other specialists, and use of over the
counter drugs). We will assess the medication
documented in GP charts at baseline and follow up
and compare it with the medication data collected in
patient interviews using similarity measures as the
Jaccard coefficient [16]. We expect that the GP’s
knowledge will increase due to our intervention.
b. Patient satisfaction with GP services as measured by
the EUROPEP [17] and patient empowerment as
measured by the Health Care Empowerment
Questionnaire [18], both collected in patient
interviews. We assume that patient satisfaction and
empowerment will improve.
c. Health care utilization and costs, assessed in a
comprehensive way by the Leipzig Supply and Cost
Instrument [19] in patient interviews as well as
number of contacts with the GP and GP’s referrals to
specialists assessed in GP interviews.
Methods against bias
Selection bias will be minimised by a standardised recruit-
ment procedure (chart registry), performed by trained re-
search assistants. In order to collect the required data for
a CONSORT flow chart (for clustered trials), the full re-
cruitment process will be documented.Public registration
Before start, the study was registered in a public internet
trial archive (ISRCTN46272088).
Blinding
Participants (GPs and patients) will not be blinded to
their assignment (which is practically not possible) but
will be unaware of the study hypotheses or primary out-
come measures.
Standardization of assessments
To ensure high data quality assessors will be trained on
standardised patients. The personnel of the participating
practices will not be involved in the collection of data.
Monitoring
An independent monitor (Institute for Biometry, Hannover
Medical School) will conduct data monitoring to ensure
high quality data in adherence to the study protocol.
Detection bias
The statistical analysis of endpoints will be performed by
a statistician blinded to group assignment.
GPs of the control group will be offered the two train-
ing sessions at the end of the intervention in order to
avoid a possible lack of motivation for recruitment and
documentation. Furthermore they will get the same fi-
nancial incentive as the GPs of the intervention group.
Stopping rules
As the planned intervention does not introduce any spe-
cific therapeutic changes but focuses at intensifying the
doctor-patient relation and over-thinking of therapeutic
aims negative effects are very unlikely. However, the fol-
lowing stopping rule will be implemented and monitor-
ing will cover these events at group level:
 if the average rate of hospital admissions increases
more than 30% in any one group.
Sample size/power calculations
For the sample size estimation of both endpoints an
α=0.025 is assumed in order to adjust for multiple testing.
The sample size calculation is based on preliminary ana-
lyses of the baseline assessment of the MultiCare Cohort
study, which used the same inclusion criteria that are
scheduled for this trial and also recruited patients via GP
surgeries. In the MultiCare Cohort study patients aver-
agely used 7.26 ± 3.5 medications (Median 7). We expect
a mean reduction of 1.5 drugs per patient in the interven-
tion group (difference baseline – follow-up) and no
change (mean reduction 0) in the number of drugs in the
control group (effect-size: 0.429). A common standard de-
viation of 3.5 drugs is assumed. Based on the data of the
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ρ=0.14 and a minimum of 10 patients per GP are targeted.
Under these assumptions and with α=0.025 and a power
of 80% totally 48 GPs (475 patients) are necessary to de-
tect the expected difference (2-sided t-test for equal var-
iances). Given a drop-out rate of 20%, 594 patients (and
60 GP surgeries) are needed altogether. The dropout rates
in other multicenter studies of the principal investigators
are comparable (e.g. AgeCoDe: 16% within 1.5 years).
Regarding the other primary endpoint it is assumed
that health related quality of life will not be inferior in
the intervention group compared with the control group
at the end of the intervention. On the instrument used
(EQ-5D value set UK [20]) -0.59 till 1.0 points can be
achieved. At the baseline assessment of the MultiCare
Cohort study patients scored 0.68 ± 0.30 points. For
testing non-inferiority it is assumed that the mean score
of the intervention group at the end of the intervention
is at most half a standard deviation (i.e. 0.15 points) less
than that of the control group. Given a standard devi-
ation of 0.30, an α=0.025, a power of 80%, an intra-
cluster correlation of ρ=0.14, 128 patients are needed
(1-sided test). Considering a design effect of 2.26 (mini-
mum of 10 patients per GP) and a dropout rate of 20%
we would need 362 patients altogether. As this number
of patients is smaller than that for the other primary
endpoint, the inclusion of 600 patients will be sufficient
also for this health related quality of life endpoint. Statis-
tical analyses will be on the intention to treat basis.
Statistical analyses
Because of the cluster randomisation hierarchic multi-
level models with GP as random effect (e.g. mixed model
analysis of variance) will be applied for the statistical
analyses of primary and secondary endpoints. Possible
baseline imbalances and confounding variables will be
controlled by adjustment. The data will be analysed
according to the intention-to-treat principle. Because of
the two primary endpoints Bonferroni correction will be
applied to adjust for multiple comparisons.
Quality assurance and safety
Reliability trainings and checks will be performed before
starting the study and subsequently yearly with the
whole staff involved in interviewing and data collection.
IT, data management and quality assurance will be
provided by the Institute of Biometry, Hannover Medical
School. Quality assurance consists of procedures for pre-
vention of insufficient data quality, detection of inaccur-
ate or incomplete data and action to improve data
quality, e.g. user training sessions, automatic plausibility
and integrity checks within the remote data entry system
and data error reports for the local centres. In addition
the centres will regularly receive feedback by qualityreports. Two monitoring and training visits per centre
are planned: one at the beginning of the trial and one
after finishing the recruitment phase. In addition a ran-
dom sample of paper questionnaires (5%) will be com-
pared with the data entries in the database. Adverse
events will be monitored and reported.
Ethics approval
The study was approved by the Ethics Committee of
the Medical Association of Hamburg in July 2011
(Approval-No. PV3788).
Discussion
Justification of primary outcome measures
On the one hand, the number of pharmaceutical agents
taken shall be at a minimum with respect to patient
safety (the less non-essential medication, the lower the
risk of adverse effects and interactions) and health care
costs. On the other hand, necessary drugs should be
used reliably by the patients. This is often not the case
as the average rate of non-adherence to chronic medica-
tion has been estimated at about 50% [21]. According to
Spinewine et al. [22] “the evidence is mixed and contra-
dictory that inappropriate prescribing, defined by
process measures, is associated with adverse patient out-
comes.” However, this may be largely due to important
limitations in the methods of the studies reviewed.
Therefore, despite the poor evidence, there is a consen-
sus that reduction of harmful drug load and reliable use
of needed drugs are of great importance, especially in
patients with multimorbidity [23].
There is growing evidence that the phenomenon of
polypharmacy and low quality of drug use is substan-
tially due to mis-communication (or even non-commu-
nication) in the doctor patient interaction [24,25]. Also,
agenda divergence may lead to more referrals to (or self
directed use of ) specialists with further drug prescrip-
tions, of which the GP may not be informed. The
problem of specialists prescribing medication without
informing the GP is typical for Germany and some other
countries in which there is practically free access to am-
bulatory working specialists. Also, Spinewine et al. [19]
highlight communication as a core of future interven-
tions: “Although several studies addressed communica-
tion between different health-care providers through
multi-disciplinary approaches, we believe the issue of
communication between prescribers and their patients
has been overlooked. (. . .) The involvement of patients
or their carers in decision making relevant to prescribing
is a real challenge, especially in a frail elderly population.
However, this approach seems promising.”
For these reasons the number of pharmaceutical agents
taken was chosen as a primary endpoint, which – in con-
trast to subjective measures - can be collected with high
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agents taken can be reduced. However, in order to include
a measure that reflects the subjectivity of the patient we
will also measure the health related quality of life. It is
assumed that a reduction of medications used will not im-
pair quality of life.
Justification of secondary endpoints
Further we expect that the intervention will influence sub-
jective measures like patient satisfaction with the services of
the GP or patient empowerment. The instruments chosen
for measuring the secondary endpoints are all validated and
frequently used in high quality studies. However, subjective
measures are not widely acknowledged as good primary
endpoints as they always show validity problems. Therefore
these parameters were chosen as secondary endpoints.
We also expect that the intervention will increase effi-
ciency and effectiveness of health care utilization. On the
one hand, health care costs could be reduced due to a re-
duction of medication, due to focussing on treatment
goals that are important for the patient (and dropping
treatments that are not relevant in this context) or due to
gaining better disease control through regular encounters
with less unplanned hospital admissions (higher effi-
ciency). On the other hand costs could rise as a result of
so far unmet health problems and needs of support, e.g. if
nursing services are required (higher effectiveness). There-
fore health care utilization and costs will be assessed in a
comprehensive way by the Leipzig Supply and Cost In-
strument, which already is used successfully in the Multi-
Care Cohort Study [9] and the AgeCoDe-study [16].
Conclusions
The MultiCare AGENDA study will show if enhancing the
doctor-patient-dialogue and identifying the patient’s agenda
and needs can increase the quality of care for patients with
multimorbidity. We presume that our intervention can
lower the number of pharmaceuticals without impairing
the patients’ quality of life. Other possible effects include a
better knowledge of GPs about their patients’ medication,
a higher patient satisfaction and a more effective and/or ef-
ficient health care utilization.
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